无创基因分型与早期疾病动力学证明伊布替尼联合免疫化疗在TRIANGLE试验套细胞淋巴瘤患者中的疗效
TRIANGLE试验显示一线免疫化疗联合伊布替尼(Ibru-R-chemo)在年轻套细胞淋巴瘤患者中具优效性。本研究对57例患者行cfDNA靶向捕获测序及cfDNA/外周血MRD检测,发现治疗前cfDNA与ctDNA水平可预测结局,CTC清除较ctDNA清除更频繁迅速,qPCR法MRD对结局预测最强,Ibru-R-chemo似可克服TP53突变介导的风险并诱导早期MRD反应。
要点
- 治疗前cfDNA与ctDNA水平可预测套细胞淋巴瘤患者结局。
- CTC清除较ctDNA清除更频繁且迅速,qPCR法MRD对结局预测最强。
- Ibru-R-chemo似可克服TP53突变介导的风险并诱导早期MRD反应。
核心结论
- 除直接抗B细胞疗效外,伊布替尼通过重建有效免疫系统并增强免疫细胞控制来提高化疗效率。
研究设计与样本
- 对TRIANGLE试验(NCT02858258)中57例套细胞淋巴瘤患者,采用靶向捕获测序行cfDNA基因分型,并以靶向测序和qPCR检测cfDNA及外周血中的MRD。
主要发现
- 治疗前cfDNA和ctDNA水平可预测结局,并精确完成所有患者的基因分型。
- CTC清除在各治疗组中均较ctDNA清除更频繁且迅速。
- 中期分期时,55%患者ctDNA阳性,而qPCR和免疫球蛋白基因(IG)-NGS检测CTC阳性率分别为35%和41%。
- 诱导结束时,43%患者ctDNA阳性,而qPCR和IG-NGS检测CTC阳性率分别为15%和25%。
- Ibru-R-chemo似可克服TP53突变介导的风险(风险比1.9 vs 10),并在中期分期诱导早期MRD反应,表现为CTC清除率(71% vs 57%)和ctDNA清除率(59% vs 24%)提高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Adding ibrutinib to first-line immunochemotherapy (Ibru-R-chemo) showed superiority in younger mantle cell lymphoma (MCL) patients in the TRIANGLE trial (NCT02858258). To investigate response mechanisms and kinetics across treatment arms, we genotyped 57 patients from cell-free (cf)DNA using targeted-capture sequencing and investigated measurable residual disease (MRD) in cfDNA and peripheral blood by targeted-sequencing and qPCR. Pre-treatment cfDNA and circulating tumor (ct)DNA levels predicted outcomes, and precisely genotyped all patients. Circulating tumor cell (CTC)-clearance was more frequent and rapid than ctDNA-clearance across arms. At interim staging (IS), 55% of patients were ctDNA-positive while 35% and 41% were CTC-positive by qPCR and immunoglobulin gene (IG)-NGS. At end of induction, 43% were ctDNA-positive, while 15% (qPCR) and 25% (IG-NGS) were CTC-positive. MRD by qPCR was most predictive for outcomes. Ibru-R-chemo seemed to overcome TP53mut-mediated risk (hazard ratio 1.9 vs. 10) and induce early MRD response, represented by enhanced CTC (71% vs. 57%) and ctDNA clearance (59% vs. 24%) at IS. Flow-cytometry-based immunomonitoring showed ibrutinib's influence on inhibitory T-cell phenotypes, showing ≥25% reduction in PD1+ and PD1+ KLRG1+ CD4+-T-cells in four patients. Taken together, besides direct anti-B-cell efficacy, ibrutinib improves chemotherapy efficiency by reconstituting an effective immune system and enhancing immune cell control.
引用
- Khouja M, Genuardi E, Ferrero S, et al. Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial. Leukemia. 2025. PMID: 41184633. doi:10.1038/s41375-025-02787-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。